CRISPR Therapeutics 2025 Q3 Earnings Revenue Surges 48.3% Despite Widening Loss

CRISPR Therapeutics (CRSP) reported fiscal 2025 Q3 earnings on Nov 10, 2025, with revenue exceeding expectations by 48.3% to $0.89 million. The company, however, posted a widened net loss of $106.44 million, driven by escalating R&D and collaboration costs. Vertex Pharmaceuticals, its key partner, forecasts CASGEVY to generate over $100 million in 2025 revenue, signaling commercial traction despite ongoing financial headwinds.

Revenue

Grant revenue accounted for the entirety of CRISPR Therapeutics’ total revenue of $889,000 in Q3 2025, marking a 47.7% increase from $602,000 in the same period last year. This growth reflects the company’s reliance on research funding amid limited commercial product sales.

Earnings/Net Income

CRISPR Therapeutics’ losses deepened to $1.17 per share in Q3 2025, a 15.8% wider loss compared to $1.01 per share in 2024 Q3. The net loss expanded to $106.44 million, a 23.9% increase from $85.94 million in the prior year. Despite a 28.3% reduction in R&D expenses to $58.9 million, collaboration costs rose to $57.1 million, underscoring the financial strain of advancing gene-editing therapies. Despite a 48.3% revenue increase, the company’s net loss widened by 23.9% to $106.44 million, underscoring ongoing financial challenges.

Post-Earnings Price Action Review

CRISPR Therapeutics’ stock declined 2.56% post-earnings despite a 48.3% revenue increase, suggesting market skepticism toward its financial health. The strategy of buying CRSP when revenue misses and holding for 30 days showed a positive result, driven by a 48.3% YoY revenue rise and institutional confidence, including a 115.3% increase in holdings by Vestmark Advisory Solutions. While the net loss widened by 23.9%, analysts like HC Wainwright maintain a “buy” rating with an $80 target price, citing long-term potential in gene-editing innovation. Risks include short-term volatility and high R&D costs, but the 30-day holding period allows for potential rebounds based on CASGEVY’s commercial growth and upcoming clinical milestones.

CEO Commentary

Samarth Kulkarni highlighted CASGEVY’s global momentum, with nearly 300 patient referrals and 39 infusions. Positive Phase 1 data for CTX310 in cardiovascular disease and the SyNTase platform’s potential were emphasized. Strategic priorities include advancing in vivo programs, expanding manufacturing, and leveraging partnerships like the Sirius collaboration for siRNA therapies.

Guidance

Vertex expects CASGEVY to generate over $100 million in 2025 revenue, with significant 2026 growth. Pediatric Phase 3 data will be presented at ASH in December, and CTX460’s clinical trial is planned for mid-2026. CRISPR Therapeutics holds $1.9 billion in cash, providing a strong runway for development.

Additional News

1. Strategic Collaboration: CRISPR Therapeutics expanded its partnership with Sirius Therapeutics, advancing SRSD107, a Factor XI-targeting siRNA therapy for thromboembolic disorders. Phase 2 trials are ongoing in Europe.

2. Clinical Progress: Positive Phase 1 data for CTX310, targeting cardiovascular disease, were published in The New England Journal of Medicine, reinforcing the company’s in vivo gene-editing platform.

3. Investor Confidence: Institutional holdings increased, with Vestmark Advisory Solutions boosting its stake by 115.3% and ARK Investment Management also raising positions, signaling optimism about CRSP’s long-term potential.